Janssen submits EMA filing for bladder cancer treatment
Drug Discovery World
SEPTEMBER 14, 2023
6,7 “For patients with advanced UC, including FGFR-driven tumours, outcomes remain poor and treatment options are limited; therefore, there is a need for novel, targeted therapies,” said Martin Vogel, EMEA Therapeutic Area Lead Oncology, Janssen-Cilag GmbH. “We N Engl J Med 2019; 381(4):338-348. Expert Review of Clinical Pharmacology.
Let's personalize your content